scholarly journals A surgical case of superficial esophageal basaloid cell carcinoma

2016 ◽  
Vol 24 (2) ◽  
pp. 42-46
Author(s):  
Takeshi Shimakawa ◽  
Yoshihiko Naritaka ◽  
Miki Miyazawa ◽  
Asako Shimazaki ◽  
Shinichi Asaka ◽  
...  
2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 188-188
Author(s):  
Marta De Vega ◽  
Carlos Miliani ◽  
Juan Rodriguez Vitoria ◽  
Juan Antonio Martinez-Piñeiro ◽  
Fernando Pereira

Abstract Background Basaloid cell carcinoma of the esophagus (BSCCE) is a rare (0.07–4%) poorly-differentiated variety of squamous cell carcinoma (SCC), more aggressive and with a worse prognosis than typical SCC. There are no published studies on the best therapeutic option for these tumors or on of the effectiveness of Neoadjuvant chemoradiotherapie; so there is no standard treatment. We describe the characteristics and the therapeutic strategy applied to a patient with an avanced basaloid squamous cell carcinoma of the distal esophagus. Methods A 70-year-old woman with dysphagia and severe malnutrition was diagnosed with locally advanced esophageal cáncer of lower esophagus The biopsy indicated moderately differentiated basaloid cell carcinoma. The clinical diagnosis was cT4NxM0, We decided multimodal treatment with curative intent: Neoadjuvant chemoradiotherapie at a dose of 41.4 Gy and concomitant carboplatin and pacliotaxel 5 cycles (CROSS scheme) plus surgery. Results PET-TAC post-neoadjuvant re-evaluation showed partial morphological response (reduction of tumor metabolism in 34.7%). 6 weeks after radiochemotherapy we performed a three fields total esophagectomy. Postoperative course without incidents. The pathological diagnosis was BASALOID cell CARCINOMA located in distal esophagus of 10 cm long with 30% tumor residual; it affects gastro-oesophageal junction. Stage TNM 7th ed: ypT3 N0 (0/17) L0V1R0 Our patient is fine and without evidence of recurrence after 15 meses. Conclusion Basal squamous cell carcinoma is more common in men around 60 years old, being rare in older women. They are located more frequently in the middle than in lower esophagus. They are tumors of poor prognosis (poorly differentiated, locally advanced and with an aggressive biological behavior that predisposes to early metastasis) although the latest publications relate the prognosis especially with the stage of the tumor. There are no published data about the use of Neoadjuvant treatment for these tumors. We have carried out a multimodal treatment (Cross scheme) followed by surgery with clinical, radiological (PET-TAC) and pathological response (30% of residual tumor in the piece) CONCLUSION The multimodal treatment with Cross scheme and surgery was useful in patients with Basaloid tumor of the esophagus can be considered for patients with this type of tumor. Disclosure All authors have declared no conflicts of interest.


1991 ◽  
Vol 44 (7) ◽  
pp. 1098-1101 ◽  
Author(s):  
N. Doi ◽  
K. Miyachi ◽  
M. Azuma ◽  
M. Nanba ◽  
S. Ikeguchi ◽  
...  

2013 ◽  
Vol 74 (6) ◽  
pp. 1488-1494 ◽  
Author(s):  
Yoko SANDA ◽  
Kunihiko KANEDA ◽  
Yukiko MIURA ◽  
Shunji NAKAYAMA ◽  
Katsunori KAWAGUCHI

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 7-7 ◽  
Author(s):  
Ken Kato ◽  
Hiroyasu Igaki ◽  
Yoshinori Ito ◽  
Isao Nozaki ◽  
Hiroyuki Daiko ◽  
...  

7 Background: Esophagectomy (E) is the standard of care for stage I esophageal squamous cell carcinoma (ESCC), while chemoradiotherapy (CRT) is a treatment option. A parallel-group controlled trial including randomized arms to confirm the non-inferiority of CRT to E for stage IA ESCC was conducted. Methods: Patients (pts) with thoracic ESCC, adenosquamous cell, or basaloid cell carcinoma with stage IA (T1bN0M0), age 20 to 75, performance status 0 to 1, and adequate organ function were eligible. If pts accepted randomization, they were randomly allocated to E with 2-3 field lymph node dissection (arm A) or CRT (arm B). However, if pts had a preference and refused randomization, they were allocated to pts preference arm, E (arm C) or CRT (arm D). CRT consisted of cisplatin and 5-FU, with radiation at the dose of 60 Gy concurrently. The primary endpoint was overall survival (OS) of arm A and B, secondary endpoint included OS of arm C and D using inverse probability weighting with propensity score. The planned sample size in arm A and B was 114 pts in total with one-sided alpha of 10%, power of 75% and non-inferiority margin of HR as 1.78. The sample size in arm C and D was at least 156 pts in each arm with one-sided alpha of 2.5%, power of 85% and non-inferiority margin of HR as 1.78. Results: Between December 2006 and February 2013, 379 (Arm A: 4, B: 7, C: 209 C, D: 159) pts were enrolled. Primary endpoint was not calculated due to small number of randomized arms. Patients characteristics of arm C and D were as follows; median age: 62 and 65, male (%): 82.8 and 88.1, PS 0 (%): 99.5 and D 98.1. All histologic type was SCC except one basaloid cell carcinoma in arm C. The 3- and 5-year OS were 94.7% and 86.5% in arm C, and 93.1% and 85.5% in arm D (adjusted HR 1.05; 95% CI 0.67-1.64 [< 1.78]).Treatment related death were observed in two pts in arm C and none in arm D. Conclusions: Though the accrual of randomized arms was shortened, CRT showed trend toward non-inferiority compared to E in pts preference arms. CRT is considered as a treatment option for stage IA ESCC with organ preservation. Clinical trial information: UMIN000000551.


2010 ◽  
Vol 102 (1) ◽  
pp. 147-155 ◽  
Author(s):  
Thomasina L. Bailey ◽  
Maxwell A. Fung ◽  
Regina Gandour-Edwards ◽  
William G. Ellis ◽  
Rudolph J. Schrot

2018 ◽  
Vol 2018 ◽  
pp. 1-3 ◽  
Author(s):  
Takahisa Yamashita ◽  
Makoto Morozumi ◽  
Morihiro Higashi ◽  
Shuji Momose ◽  
Jun-ichi Tamaru

Cystic nodal metastasis of renal cell carcinoma is very rare. The pathogenesis of cystic nodal metastasis is thought to involve obstruction of a lymphoid vessel draining the kidney by tumor cells and retrograde metastasis from the primary site to the lymph node along the lymphatic vessels. In this study, a surgical case of small renal cell carcinoma with retroperitoneal cystic nodal metastasis is reported.


2004 ◽  
Vol 37 (3) ◽  
pp. 290-295 ◽  
Author(s):  
Shinichi Yoshioka ◽  
Toshimasa Tsujinaka ◽  
Kazumasa Fujitani ◽  
Kunimitsu Kawahara

Author(s):  
Kazuhiro Suzumura ◽  
Yasukane Asano ◽  
Hideaki Sueoka ◽  
Ami Kurimoto ◽  
Takahiko Hashimoto ◽  
...  

1983 ◽  
Vol 33 (6) ◽  
pp. 1243-1250
Author(s):  
Kishichiro Watanabe ◽  
Akio Mukawa ◽  
Kimiomi Miyazaki ◽  
Kenji Tsukahara

Sign in / Sign up

Export Citation Format

Share Document